Claire Mazumdar - 16 Dec 2025 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role
Chief Executive Officer, Director
Signature
/s/ Lara Meisner, Attorney-in-Fact
Issuer symbol
BCAX
Transactions as of
16 Dec 2025
Net transactions value
+$160,884
Form type
4
Filing time
18 Dec 2025, 18:02:57 UTC
Previous filing
25 Nov 2025
Next filing
04 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mazumdar Claire Chief Executive Officer, Director BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON /s/ Lara Meisner, Attorney-in-Fact 18 Dec 2025 0002034671

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCAX Common Stock Options Exercise $160,884 +29,500 +9.5% $5.45 339,392 16 Dec 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCAX Stock Option (Right to Buy) Options Exercise $0 -29,500 -5% $0.000000 565,512 16 Dec 2025 Common Stock 29,500 $5.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date.